40 results about "Oral tablets" patented technology

The present disclosure is directed to oral tablet of ribociclib including its salt(s). One embodiment of the present disclosure is directed to tablet of ribociclib with high drug load with an immediate release profile. One embodiment of the present disclosure is directed to coated tablet of ribociclib. Another embodiment of the present disclosure is directed to coated tablet of ribociclib where the coating is an aqueous moisture barrier coating (e.g., Opadry® amb II coating where the coating is PVA based).

The present invention discloses modified-release bilayer tablets consisting of two layers, layer 1 consisting 500 mg sustained release metformin and layer 2 consisting 250 mg normal release metformin and 5mg / 10mg delayed-release dapagliflozin. This formulation is meticulously designed to regulate blood glucose levels effectively over an extended period. Immediate-release metformin swiftly addresses acute glucose spikes, while sustained-release metformin ensures prolonged glucose control, minimizing fluctuations throughout the day. The delayed-release dapagliflozin component allows for controlled and timed release, managing persistent hyperglycemia synergistically with metformin. By optimizing efficacy and minimizing glucose fluctuations, this innovative formulation offers a promising solution for stable glycemic control in individuals with diabetes. Present invention aims to improve patient outcomes and enhance overall quality of life by maintaining stable glucose levels and reducing the risk of complications associated with uncontrolled diabetes.

This utility model discloses a raw material preparation device for oral tablet processing, relating to the field of tablet processing technology. It includes: a device support frame for mounting and fixing a lifting sleeve mechanism, a flow guiding and output mechanism, and a pushing and stirring mechanism; and a lifting sleeve mechanism comprising an outer sleeve slidably disposed vertically inside an upper flow guide hopper and slidably sleeved on the outside of a rotating disk and a sieve plate. Two sets of synchronously moving lifting components are arranged on both sides of the outer sleeve. Each set of lifting components includes an L-shaped side plate fixedly disposed on the side of the worktable, and an electric push rod is fixedly disposed at the bottom of the L-shaped side plate. This utility model can conveniently output large-particle raw materials and prepared raw materials after screening and preparation, saving manpower while effectively improving preparation efficiency. It also provides a more thorough discharge with less residue.

This disclosure provides crystalline forms of a compound of Formula (A), and pharmaceutical compositions thereof. This disclosure further provides methods for their preparation and use in methods of treatment, prophylaxis, or delay in onset or progression of HIV infection or AIDS in a subject. This disclosure further provides dosage forms, such as oral tablets, of a compound of Formula (A) and its crystalline forms.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are methods for making the tablets comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers, e.g., comprising slugged tablets, wherein the slugged tablets have greater than 90, 91, 92, 93, 94, 95, 96, 97, 98, or 100% of the slugged tablets meet specifications; target width of 10 to 12 mm, or 11 mm; target weight of approximately 475 to 525 mg; and thickness range of approximately 4 to 6 mm, 4.5 to 5.5 mm or 5 mm. Pharmaceutical composition(s) in the form an oral tablet or capsule comprising N-acetylcysteine amide (NACA) for administration of the pharmaceutical composition to a human.

The invention belongs to the field of medicines, and particularly discloses application of ImP (Imidazole Propionic Acid) in preparation of medicines for preventing or treating metabolic syndrome related diseases, aiming at the problems that the existing anti-obesity medicines are large in side effect, limited in curative effect and the like, and metabonomics research finds that the peripheral blood ImP level in a high-fat diet induced obesity model is remarkably reduced. A zebra fish model (250 [mu] M) and a human fat cell experiment (10-1000 [mu] M) prove that ImP significantly reduces the lipid accumulation rate by more than 40% (Plt; 0.01) of the substrate. The pharmaceutical composition can be prepared into dosage forms such as oral tablets (for example, each tablet containing 50 mg of ImP), sustained-release injections and the like, and can be theoretically combined with orlistat and other medicines for use. Compared with the traditional therapy, the invention reveals the lipid metabolism regulation function of ImP for the first time, and the ImP has the advantages of strong targeting property (IC50 = 120 mu M), high safety (LD50gt; 2000mg / kg) and the like, and a brand new microbial metabolite intervention strategy is provided for obesity and related metabolic diseases.

The invention relates to amitriptyline gel as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides amitriptyline gel. The amitriptyline gel is prepared from the following components in parts by mass: 2 to 8 parts of amitriptyline hydrochloride, 16 to 24 parts of glycerol, 2 to 8 parts of hydroxypropyl methylcellulose, 16 to 24 parts of 70 to 80 percent ethanol solution, 0.05 to 0.15 part of ethylparaben, 0.2 to 0.8 part of laurocapram and 36 to 64 parts of water. The amitriptyline gel plaster prepared from the amitriptyline gel can effectively relieve postherpetic neuralgia, and compared with traditional oral tablets, the amitriptyline gel plaster can effectively reduce side effects.

The present invention relates to a pharmaceutical composition comprising ramelteon and a nasal administration formulation. The pharmaceutical composition comprises ramelteon and polyethylene glycol. The pharmaceutical composition of the present invention has high stability and can be used to prepare a pharmaceutical formulation that meets the specifications for nasal administration formulations. Compared with oral tablets, the pharmaceutical composition of the present invention features improved bioavailability of ramelteon and a targeted concentration in brain tissue.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fdlers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / mL after administration of the pharmaceutical composition to a human.

Provided herein are tablet(s) comprising N-acetylcysteine amide (NACA) and a NACA-acceptable, biocompatible excipient and optionally one or more pharmaceutically acceptable additives, binders, or fillers. Also provided are pharmaceutical composition(s) in the form an oral tablet comprising N-acetylcysteine amide (NACA), wherein the composition has a pharmacokinetic (PK) profile comprising mean plasma concentrations of NACA range from about 200 to 1200 ng / ml after administration of the pharmaceutical composition to a human.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

The invention related to an oral colon targeted tablet comprising a tablet core coated with a film-coating composition, said tablet core comprising a powder of a therapeutic protein co-dried with a substituted cyclodextrin, and said film-coating coating composition comprising a water-insoluble polymer and a soluble fiber. It also related to a process for making such tablets, and to the use thereof as a medicament.

Provided are oral tablets comprising naproxen sodium, mannitol, a superdisintegrant, and a lubricant. The oral tablets described herein to not comprise a glidant (e.g. colloidal silicon dioxide). These oral tablets may be manufactured using the process of mixing naproxen sodium, mannitol, a superdisintegrant, and magnesium stearate in a continuous in-line mixer to form a tableting mixture; transferring the tableting mixture to a tablet press including three or more compression rollers; and pressing the tableting mixture into naproxen sodium tablets.

The present invention provides a drug for treating non-small cell lung cancer, belonging to the field of medicine. The drug's raw materials include gefitinib and andrographolide, wherein the concentration of gefitinib is 12-20 μM and the concentration of andrographolide is 200-250 μM. The drug is in the form of an oral liquid preparation or an oral tablet. Experimental results show that the drug provided by the present invention has a significant inhibitory effect on the expression of apoptosis-related proteins and genes in PC9 / G cells, with a greater inhibitory effect than gefitinib or andrographolide alone, indicating a certain synergistic relationship between the two.

The invention relates to an orally administered tablet suitable for active pharmaceutical ingredients comprising a particle population, the particle population comprising a) directly compressible sugar alcohol particles (DC), b) not directly compressible sugar alcohol particles (non-DC) and c) particles comprising a gum base, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in saliva-induced generation upon chewing the tablet, wherein the tablet is designed to be chewed into a coherent residue containing water-insoluble components.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the prevention of a human immunodeficiency virus (HIV) infection in a patient.

The invention provides an OAB-14 composition which comprises OAB-14, the particle size d (0.5) of the OAB-14 is 1-2998 nm, and the particle size d (0.9) of the OAB-14 is 2-5532 nm. The OAB-14 is further prepared into various dosage forms such as oral tablets, capsules, pellets, granules, dry suspensions, suspensions and the like. The particle size d (0.5) of the OAB-14 raw material is reduced to be 1-2998 nm, the particle size d (0.9) of the OAB-14 raw material is reduced to be 2-5532 nm, the surfactant is added, the dissolution rate of the raw material is increased, the adhesion of the raw material on the gastrointestinal wall is improved, the bioavailability is increased by 217.91%, the same medicine effect is achieved, and the dosage of the suspension is 40% of that of the raw material medicine.

Pharmaceutical compositions of semaglutide or a salt thereof for intranasal administration for the treatment of diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), or neurodegenerative diseases. The method of delivering semaglutide by the intranasal route avoids repeated injections and improves systemic absorption of semaglutide compared to oral tablets.

The present disclosure relates to pharmaceutical formulations comprising a HIV capsid inhibitor and methods for the treatment or prevention of a human immunodeficiency virus (HIV) infection in a patient.

The invention relates to the technical field of microorganisms, and particularly discloses an acetobacter xylinum HNNB6-Se capable of resisting selenium and producing red selenium-rich nano cellulose, and the preservation number of the acetobacter xylinum HNNB6-Se is GDMCC (China General Microbiological Culture Collection Center) 66552. The strain is obtained by performing sodium selenite gradient stress domestication on an original strain acetobacter xylinum HNNB6, and can grow in a culture medium containing 1-200 [mu] g / mL of sodium selenite and synthesize the red selenium-rich nano bacterial cellulose. The selenium content in the produced nano cellulose (BC) reaches 50-5000 micrograms per gram by dry weight, and the produced nano cellulose (BC) is in stable red (the chromatic value a * is 0.5-25). The red selenium-rich nano bacterial cellulose has a selenium bioaugmentation function, and has outstanding application value in functional food selenium supplements (such as oral tablets and gel foods), medical materials (such as wound dressings) and beauty makeup products.

Described herein are immediate release oral tablet compositions for the treatment of TYK2 mediated diseases. In some embodiments, the TYK2-mediated disease is an autoimmune disease, an inflammatory disease, a proliferative disease, an endocrine disease, a neurological disease, or a disease associated with transplantation.

The present application provides a sublingual tablet composition of lumeritopine tosylate and a preparation method thereof. The sublingual tablet composition of lumeritopine tosylate comprises the following ingredients by weight percentage: lumeritopine tosylate 2% to 15% (1.4 mg / tablet to 10 mg / tablet), filler 15% to 75%, disintegrant 2% to 10%, surfactant 0.1% to 10%, lubricant 0.5% to 2%, glidant 0.5% to 2%, and flavoring agent 0.5% to 2%. The sublingual tablet composition is prepared by direct compression of powder. The sublingual tablet composition has good taste, does not irritate mucosa, is rapidly absorbed under the tongue, and has significantly higher bioavailability than ordinary oral tablets.

The invention relates to a pharmaceutical composition containing ramelteon and a nasal delivery preparation. The pharmaceutical composition comprises ramelteon and polyethylene glycol. The pharmaceutical composition disclosed by the invention is high in stability, can be used for preparing a pharmaceutical preparation meeting the quality requirement of a nasal delivery preparation, and can be used for improving the bioavailability of ramelteon and the drug concentration of targeted brain tissues compared with oral tablets.

The present invention relates to a sustained-release formulation of ruxolitinib or a pharmaceutically acceptable salt thereof which is useful for the treatment of Janus kinase-associated diseases such as myeloproliferative disorders, and a method for preparing same.

The present disclosure provides compositions of agglomerated crystalline salts of medium chain fatty acids having improved properties relative to commercially available salts. These salts are useful as excipients in pharmaceutical oral dosage forms, including as penetration enhancers. The present disclosure provides a sodium caprate crystalline composition having improved powder flowability and compression behavior. The disclosure further provides oral tablets comprising these sodium caprate compositions, including tablets substantially free of any tabletting aid excipients. In various embodiments, these tablets exhibit superior tensile strength and tableting properties than conventional tablets.

The invention provides a nemategravir inhalant and a preparation method and application thereof, and belongs to the technical field of medicines.The nemategravir inhalant comprises nemategravir, water, a surfactant and an auxiliary, has the high lung deposition rate, good stability and low irritation and can overcome the defects of existing nemategravir oral tablets. After the nemategravir inhalant prepared by the embodiment of the invention is inhaled, the residence time of nemategravir in lung tissues can be maintained for more than 12 hours.